BioSpace News Archive

Univar Solutions Inc., a leading global chemical and ingredient distributor and provider of value-added specialty services, will host “Innovation Day” on June 22.

Baxter International Inc., a global medtech leader, will host a conference call to discuss its second-quarter 2022 financial results on Thursday, July 28, 2022 at 7:30 a.m. Central Time.

Orphazyme A/S, reports its financial results for the period from January 1, 2021, to December 31, 2021, and publishes its Annual Report.

Like hundreds of thousands of Americans, Kelley Flanagan developed mysterious health symptoms with, seemingly, no answers, that began in fourth grade but increased after her season of The Bachelor.

Sciwind Biosciences Co., Ltd. announced that two abstracts have been accepted for poster presentations at The International Liver CongressTM 2022, the Annual Meeting of the European Association for the Studies of the Liver taking place June 22-26 in London, United Kingdom.

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that it has entered into an exploratory supply agreement with ATMA Journey Centers (“ATMA”), a privately held facilitator of psilocybin-assisted therapy and practitioner training services for palliative care and mental health conditions based in Calgary, Alberta.

SPO Global Inc., a healthcare and biotech company, provides an in depth discussion of the company’s medical devices.

Vaxart, Inc. announced that its 2022 annual meeting of stockholders has been adjourned to Wednesday, July 6, 2022 at 9:30 a.m. Pacific Time with respect to all proposals described in Vaxart’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 28, 2022.

Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), (“Alpha Tau” or the “Company”), announced today that the U.S. Food and Drug Administration (FDA) has conditionally approved the Company’s Investigational Device Exemption (IDE) application to initiate its multi-center pivotal study for the treatment of recurrent cutaneous Squamous Cell Carcinoma (SCC) using the Alpha DaRT.

Innova Medical Group, Inc., today announced it successfully earned its CE mark certification (certificate N° 39032) of the Innova SARS-CoV-2 Antigen Rapid Qualitative Self-Test through GMED LNE Group, a leading certification organization and a distinguished Notified Body of the European Commission covering a vast range of products covered under both Invitro Diagnostic and Medical Device Regulations.